EPHA2 and cancer: showed the improved efficacy of the combination treatment of FAP CAR‐T cells and EphA2 CAR‐T cells, leading to the clearance of FAP+ tumor‐associated fibroblasts and enhancing the treatment outcome of CAR‐T cells targeting the tumor‐associated antigen EphA2 locally and systemically.[91] Matrix components such as collagens and HA are also being investigated as possible targets to overcome physical barriers and further facilitate cancer immunotherapy using cell‐based delivery systems.